GSK in £1.2bn deal for sleeping pill rights
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The UK's biggest pharmaceutical group, GlaxoSmithKline, is to pay up to £1.2bn for the rights to develop and sell almorexant, an anti-insomnia treatment in its final stage of testing.
GSK will initially spend £66m to help the drug's Swiss maker, Actelion, push the sleeping pill through its phase three trials in Europe. Assuming almorexant passes the licencing requirements, Glaxo's will be liable to pay additional sums relating to sales and other applications for the treatment.
A spokesperson for the group said yesterday the deal was unlikely to result in the whole £1.2bn being paid and declined to comment on what other trials were likely for almorexant.
According to analysts at Dresdner Kleinwort, almorexant is expected to be ready for market by 2011. With 80 million sufferers in the United States alone, experts at JP Morgan Cazenove argue that the US market for insomnia treatments is worth up to $1.2bn.
GSK and Actelion have agreed to continue to pool research into insomnia treatments, although at present this does not extend beyond almorexant.
Analysts covering GSK had one eye on the group's interim results, due next week. It will be one of the first chances the group's chief executive, Andrew Witty, has had to talk directly to shareholders who have seen the stock fall steadily over the past 12 months.
Jeremy Batstone-Carr, an analyst at Charles Stanley, reckons that Mr Witty will take the opportunity to outline his strategy, two months into the job.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments